401519-96-8
| 中文名称 | 401519-96-8 |
|---|---|
| 中文同义词 | 化合物 T19471;化合物 NCX 1000 |
| 英文名称 | NCX 1000 |
| 英文同义词 | NCX 1000;Cholan-24-oic acid, 3,7-dihydroxy-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propen-1-yl]phenyl ester, (3α,5β,7β)- |
| CAS号 | 401519-96-8 |
| 分子式 | C38H55NO10 |
| 分子量 | 685.86 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 401519-96-8.mol |
| 结构式 |  |
401519-96-8 性质
| 沸点 | 758.3±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.198±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 酸度系数(pKa) | 14.79±0.70(Predicted) |
| 颜色 | 白色至米白色 |
|
Human Endogenous Metabolite
|
NCX-1000 (15 mg/kg, p.o.) prevents ascite formation, reduces collagen deposition in CCl4-treated rats. NCX-1000 administration almost completely reverts portal hypertension induced by CCl4, and reduces portal pressure in cirrhotic rats. NCX-1000 reverts HSC contraction induced by FCS, and also inhibits MCP-1 release from HSCs stimulated with TNF-α and IFN-γ. NCX-1000 (28 mg/kg, p.o.) decreases portal pressure without affecting mean arterial pressure and heart rate in rats. NCX-1000 also reduces vasoconstriction by 60% caused by 30 μM NE in rats. Administration of NCX-1000 to BDL and sham operated rats results in a similar increase of nitrite/nitrate and cGMP concentrations in the liver.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/08/19 | HY-U00023 | 401519-96-8 NCX 1000 | 401519-96-8 | 1 mg | 2906元 |